Zitser J, Thaler A, Inbar N, Gad A, Faust-Socher A, Paleacu D, Anca-Herschkovitch M, Balash Y, Shabtai H, Ash EL, Merkin L, Manor Y, Kestenbaum M, Bar David A, Peretz C, Naiman T, Bar-Shira A, Orr-Urtreger A, Dangoor N, Giladi N, Gurevich T. Two Ethnic Clusters with Huntington Disease in Israel: The Case of
Mountain Jews and Karaites.
NEURODEGENER DIS 2017;
17:281-285. [PMID:
28848105 DOI:
10.1159/000479375]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 07/10/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND
Worldwide prevalence estimates of Huntington disease (HD) vary widely, with no reliable information regarding the Jewish population in Israel.
METHODS
This specialized tertiary single-center cross-sectional study assessed clinical, cognitive, and demographic characteristics of 84 HD patients who were treated at the Movement Disorder Unit of the Tel Aviv Medical Center, Israel.
RESULTS
Our cohort was composed of one-third Ashkenazi Jews, 27% Mountain Jews (Caucasus Jews), 18% Sephardi Jews, and 21% Karaites, with both Mountain Jews and Karaites over-represented compared to their relevant proportion in the population of the state of Israel, which is less than 1%. No between-group differences were detected regarding the number of CAG (cytosine-adenine-guanine) repeats, age at onset, disease duration, years from symptom onset to diagnosis, gender, years of education, Unified Huntington Disease Rating Scale scores, or the Montreal Cognitive Assessment scores.
CONCLUSION
We detected clustering of HD among the population treated at our Medical Center, which has the only specialized HD clinic in the country, with a high percentage of HD among 2 relatively small subpopulations of Jews: Mountain Jews and Karaites.
Collapse